- $438.66m
- $445.98m
- $99.99m
Neuropace Inc reports results for the quarter ended in December - Earnings Summary
Brief: Neuropace Reports Q4 & Full Year 2022 Financial Results
Factbox: Neuralink, other brain-chip makers face long road to FDA approval
Neuropace Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Neuropace Announces Preliminary Unaudited Fourth Quarter 2022 Revenue
Brief: NeuroPace Reports Third Quarter 2022 Financial Results, Provides A Business Update
Neuropace Inc reports results for the quarter ended in September - Earnings Summary
Brief: Neuropace Inc Files For Mixed Shelf Of Up To $150 Mln
Neuropace Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Neuropace Announces First Patient Implanted In Nautilus Pivotal Study For The Treatment Of Idiopathic Generalized Epilepsy (IGE)
U.S. RESEARCH ROUNDUP-Goodrx Holdings, Nextnav, Olo
Brief: Neuropace Sees FY 2022 Revenue $43 Million To $45 Million
Brief: Neuropace Announces Distribution Agreement With Dixi Medical Usa, Provider Of Intracranial Electrodes And Instruments For Neurosurgery
Brief: NeuroPace Reports First Quarter 2022 Financial Results
U.S. RESEARCH ROUNDUP- Beauty Health, Mister Car Wash, Nuvei
Brief: NeuroPace Reports Q4 Net Loss Per Share Of $0.44
Brief: Neuropace Announces Preliminary Unaudited Q4 And Full-Year 2021 Revenue
NASDAQ RESUMED AT 09:42 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM